Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- PMID: 26755520
- DOI: 10.1200/JCO.2015.63.7421
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
Abstract
Purpose: The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC). Exploratory biomarkers were analyzed and associated with outcomes.
Patients and methods: Seventy patients with metastatic RCC, including clear cell (ccRCC; n = 63) and non-clear cell (ncc; n = 7) histologies, received atezolizumab intravenously every 3 weeks. PD-L1 expression was scored at four diagnostic levels (0/1/2/3) that were based on PD-L1 staining on tumor cells and tumor-infiltrating immune cells (IC) with the SP142 assay. Primary end points were safety and toxicity; secondary end points assessed clinical activity per Response Evaluation Criteria in Solid Tumors version 1.1 and immune-related response criteria. Plasma and tissue were analyzed for potential biomarkers of atezolizumab response.
Results: Grade 3 treatment-related and immune-mediated adverse events occurred in 17% and 4% of patients, respectively, and there were no grade 4 or 5 events. Sixty-three patients with ccRCC were evaluable for overall survival (median, 28.9 months; 95% CI, 20.0 months to not reached) and progression-free survival (median, 5.6 months; 95% CI, 3.9 to 8.2 months), and 62 patients were evaluable for objective response rate (ORR; 15%; 95% CI, 7% to 26%). ORR was evaluated on the basis of PD-L1 IC expression (IC1/2/3: n = 33; 18%; 95% CI, 7% to 35%; and IC0: n = 22; 9%; 95% CI, 1% to 29%). The ORR for patients with Fuhrman grade 4 and/or sarcomatoid histology was 22% (n = 18; 95% CI, 6% to 48%). Decreases in circulating plasma markers and acute-phase proteins and an increased baseline effector T-cell-to-regulatory T-cell gene expression ratio correlated with response to atezolizumab.
Conclusion: Atezolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with metastatic RCC. Correlative studies identified potential predictive and pharmacodynamic biomarkers. These results have guided ongoing studies and combinations with atezolizumab in RCC.
Trial registration: ClinicalTrials.gov NCT01375842.
© 2016 by American Society of Clinical Oncology.
Similar articles
-
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10. Lancet. 2016. PMID: 26970723 Clinical Trial.
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4. Lancet. 2016. PMID: 26952546 Free PMC article. Clinical Trial.
-
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.J Clin Oncol. 2020 Jan 1;38(1):63-70. doi: 10.1200/JCO.19.01882. Epub 2019 Nov 13. J Clin Oncol. 2020. PMID: 31721643 Free PMC article. Clinical Trial.
-
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.Cancer Treat Rev. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6. Cancer Treat Rev. 2015. PMID: 25586601 Review.
-
Biomarkers to predict prognosis and response to checkpoint inhibitors.Int J Clin Oncol. 2017 Aug;22(4):629-634. doi: 10.1007/s10147-017-1122-1. Epub 2017 Apr 5. Int J Clin Oncol. 2017. PMID: 28382562 Free PMC article. Review.
Cited by
-
Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response.Nat Commun. 2024 Oct 3;15(1):8569. doi: 10.1038/s41467-024-52902-5. Nat Commun. 2024. PMID: 39362877 Free PMC article.
-
Immune Checkpoints and Graves' Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review.J Ophthalmic Vis Res. 2024 Sep 16;19(3):368-380. doi: 10.18502/jovr.v19i3.15047. eCollection 2024 Jul-Sep. J Ophthalmic Vis Res. 2024. PMID: 39359534 Free PMC article. Review.
-
Quiescence and aging of melanocyte stem cells and a novel association with programmed death-ligand 1.iScience. 2024 Sep 12;27(10):110908. doi: 10.1016/j.isci.2024.110908. eCollection 2024 Oct 18. iScience. 2024. PMID: 39351197 Free PMC article.
-
An overview of immune checkpoint inhibitor toxicities in bladder cancer.Toxicol Rep. 2024 Sep 11;13:101732. doi: 10.1016/j.toxrep.2024.101732. eCollection 2024 Dec. Toxicol Rep. 2024. PMID: 39318722 Free PMC article. Review.
-
Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors.Cancer Cell Int. 2024 Sep 10;24(1):311. doi: 10.1186/s12935-024-03496-x. Cancer Cell Int. 2024. PMID: 39256838 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials